肺癌表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的逆转

以表皮生长因子受体（EGFR）为靶点治疗非小细胞肺癌是治疗肺癌的前沿手段，其产生的获得性耐药限制了靶向药物的发展。目前已有大量的有关EGFR突变耐药的数据，利用这些数据，人们正在探讨克服EGFR靶向治疗耐药的3个基本方法：强化EGFR的抑制、EGFR抑制剂与其他靶向治疗相结合以及通过替代途径改变抗癌治疗方法。

Reversal for acquired resistance to EGFR inhibitors in lung cancer

Epidermal growth factor receptor （EGFR） inhibitors targeted therapy is the forward position means for non-small cell lung cancer. However, acquired resistance to EGFR inhibitors limits the development of targeted drugs. Using existing data on drug resistance in EGFR-mutant lung cancer, this review discusses three basic approaches for overcoming resistance to EGFR-targeted therapies： intensification of EGFR inhibi- tion, combination of EGFR inhibitors with other targeted therapies, and altering clinical management via alter- nate pathways.